原发性骨髓纤维化 中国就医指南

Primary Myelofibrosis (PMF) is a rare, chronic Philadelphia chromosome-negative myeloproliferative neoplasm characterized by clonal proliferation of abnormal hematopoietic stem cells, progressive bone marrow fibrosis, extramedullary hematopoiesis (especially in the spleen and liver), and cytopenias. Unlike secondary myelofibrosis—which arises from other underlying conditions such as polycythemia vera or essential thrombocythemia—PMF originates de novo, with hallmark driver mutations in JAK2 (≈50–60%), CALR (≈25–35%), or MPL (≈5–10%). These mutations constitutively activate the JAK-STAT signaling pathway, leading to dysregulated cytokine production, aberrant megakaryocyte differentiation, and release of fibrogenic growth factors (e.g., TGF-β, PDGF) that stimulate reticulin and collagen deposition by bone marrow stromal cells. Over time, this fibrotic remodeling impairs normal hematopoiesis, resulting in anemia, thrombocytopenia, leukoerythroblastic peripheral blood smear, splenomegaly, and constitutional symptoms including fatigue, night sweats, weight loss, fever, and early satiety. Epidemiologically, PMF affects approximately 0.5–1.5 per 100,000 individuals annually, with median age at diagnosis around 65 years; it is slightly more common in males and shows no strong ethnic predilection. Risk factors include advancing age, presence of high-risk somatic mutations (e.g., ASXL1, SRSF2, IDH1/2, U2AF1), unfavorable karyotype (e.g., complex or monosomal abnormalities), severe anemia (hemoglobin <10 g/dL), leukocytosis >25 × 10⁹/L, circulating blasts ≥1%, and transfusion dependence. Quality of life is profoundly impacted: patients frequently experience debilitating fatigue, pain from massive splenomegaly, pruritus, cachexia, and anxiety related to disease progression and risk of transformation to acute myeloid leukemia (AML)—which occurs in 10–20% of cases over 10 years. Symptom burden correlates poorly with traditional lab parameters, underscoring the importance of patient-reported outcomes in clinical assessment. Management focuses on risk-adapted strategies: low-risk patients may require only observation or supportive care (e.g., erythropoiesis-stimulating agents, transfusions, hydroxyurea for splenomegaly control), while intermediate- and high-risk patients benefit from JAK inhibitors (ruxolitinib, fedratinib, pacritinib) to alleviate symptoms and reduce splenomegaly. Allogeneic hematopoietic stem cell transplantation remains the only potentially curative option—but is limited to fit patients under age 70 with suitable donors due to significant morbidity and mortality. Ongoing research explores combination therapies, novel antifibrotic agents, and immunomodulatory approaches to modify disease biology.

# 原发性骨髓纤维化（PMF）治疗方案与费用明细（血液科）

一、非手术/药物/支持治疗方案

• •适用人群：低危/中危-1患者、老年或合并症多者、无JAK2突变或脾肿大＜10cm者
• •一线药物：芦可替尼（Ruxolitinib）——月均药费：¥18,000–¥26,000（医保谈判后自付约¥3,500–¥6,200/月）；羟基脲：¥80–¥200/月
• •支持治疗：输血（红细胞悬液¥350–¥500/单位）、EPO（¥1,200–¥2,800/支）、铁螯合剂（地拉罗司¥4,500–¥7,200/月）
• •必需检查费：骨髓穿刺+活检（¥1,200–¥1,800）、基因检测（JAK2/CALR/MPL，¥1,500–¥3,000）、脾脏超声（¥200–¥400）

二、根治性治疗方案

• •唯一根治手段：异基因造血干细胞移植（allo-HSCT）
• •适用条件：年龄≤70岁、中高危（DIPSS≥中危-2）、体能状态良好（ECOG≤2）、有HLA相合同胞或匹配无关供者
• •全套费用区间：¥350,000–¥680,000（含预处理化疗、干细胞采集/动员、回输、GVHD防治及3个月住院管理）
• •术前检查费：供受者配型（¥4,000–¥8,000）、心肺功能评估（¥2,500–¥4,200）、病毒筛查（¥1,800–¥3,000）

三、特殊/晚期/耐药方案

• •JAK抑制剂耐药者：fedratinib（未进医保，¥42,000–¥55,000/月）或临床试验入组（免费）
• •严重门脉高压/食管静脉曲张：TIPS术（¥80,000–¥120,000）；巨脾破裂急诊脾切除（¥35,000–¥52,000）

方案快速选择指南

• •预算有限/初诊低危：羟基脲+定期监测（年总支出¥2,000–¥5,000）
• •中高危且<65岁：优先评估allo-HSCT可行性（医保覆盖部分费用）
• •≥65岁或无法移植：芦可替尼联合支持治疗（年自付约¥42,000–¥75,000）